Metabolic imaging using PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 1 SUPPL., 2007, Pages

  Kudo, Takashi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Free fatty acids; Ischaemic heart disease; Metabolism; Myocardium; PET

Indexed keywords

ACETIC ACID C 11; FLUORINE 18; FLUORO 3 OXAPENTADECANOATE F 18; FLUORO 4 THIAPALMITATE F 18; FLUORO 6 THIAHEPTADECANOIC ACID F 18; FLUORODEOXYGLUCOSE F 18; PALMITIC ACID C 11; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; DIABETES MELLITUS; FATTY ACID METABOLISM; HEART FAILURE; HEART MUSCLE; HEART MUSCLE METABOLISM; HUMAN; ISCHEMIC HEART DISEASE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

FATTY ACIDS; HEART; HEART DISEASES; HUMANS; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34250712247     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0440-3     Document Type: Review

References (98)

1. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
2. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-88.
3. Krivokapich J, Huang SC, Phelps ME, Barrio JR, Watanabe CR, Selin CE, et al. Estimation of rabbit myocardial metabolic rate for glucose using fluorodeoxyglucose. Am J Physiol 1982;243:H884-95.
4. Krivokapich J, Huang SC, Selin CE, Phelps ME. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart. Am J Physiol 1987;252:H777-87.
5. Gambhir SS, Schwaiger M, Huang SC, Krivokapich J, Schelbert HR, Nienaber CA, et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med 1989;30:359-66.
6. 18F]fluoro-2-deoxy-d-glucose studies. J Nucl Med 1991;32:733-8.
7. 18F]FDG) and PET in combination with microdialysis. Diabetologia 2001;44:2171-9.
8. 18F]fluorodeoxyglucose. J Nucl Cardiol 1997;4:125-32.
9. Tamaki N, Kawamoto M, Takahashi N, Yonekura Y, Magata Y, Torizuka T, et al. Assessment of myocardial fatty acid metabolism with positron emission tomography at rest and during dobutamine infusion in patients with coronary artery disease. Am Heart J 1993;125:702-10.
10. Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1996;37:1723-30.
11. Schon HR, Schelbert HR, Robinson G, Najafi A, Huang SC, Hansen H, et al. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. I. Kinetics of C-11 palmitic acid in normal myocardium. Am Heart J 1982;103:532-47.
12. 18F]fluoro-6-thia- heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J Nucl Med 1991;32:1888-96.
13. Ebert A, Herzog H, Stocklin GL, Henrich MM, DeGrado TR, Coenen HH, et al. Kinetics of 14(R,S)-fluorine-18-fluoro-6-thia-heptadecanoic acid in normal human hearts at rest, during exercise and after dipyridamole injection. J Nucl Med 1994;35:51-6.
14. Altehoefer C, vom Dahl J, Bares R, Stocklin GL, Bull U. Metabolic mismatch of septal beta-oxidation and glucose utilization in left bundle branch block assessed with PET. J Nucl Med 1995;36:2056-9.
15. 18F]Fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscle. Eur J Nucl Med Mol Imaging 2002;29:1617-22.
16. 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: effects of hypoxia and composition of exogenous fatty acids. J Nucl Med 2006;47:173-81.
17. 18F]fluoro-3-oxa-pentadecanoate as a PET tracer of hepatic fatty acid oxidation. J Nucl Med 2000;41:1727-36.
18. 18F-fluoro-3,4-methyleneheptadecanoic acid as a PET tracer for myocardial fatty acid imaging. J Nucl Med 2005;46:297-304.
19. Renstrom B, Rommelfanger S, Stone CK, DeGrado TR, Carlson KJ, Scarbrough E, et al. Comparison of fatty acid tracers FTHA and BMIPP during myocardial ischemia and hypoxia. J Nucl Med 1998;39:1684-9.
20. Brown M, Marshall DR, Sobel BE, Bergmann SR. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation 1987;76:687-96.
21. Tamaki N, Magata Y, Takahashi N, Kawamoto M, Torizuka T, Yonekura Y, et al. Myocardial oxidative metabolism in normal subjects in fasting, glucose loading and dobutamine infusion states. Ann Nucl Med 1992;6:221-8.
22. 11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation. 1990;81:1594-605.
23. Gropler RJ, Siegel BA, Geltman EM. Myocardial uptake of carbon-11-acetate as an indirect estimate of regional myocardial blood flow. J Nucl Med 1991;32:245-51.
24. 11C-acetate. J Nucl Med 2001;42:63-70.
25. Sun KT, Yeatman LA, Buxton DB, Chen K, Johnson JA, Huang SC, et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med 1998;39:272-80.
26. 11C]Acetate as a quantitative perfusion tracer in myocardial PET. J Nucl Med 2001;42:1174-82.
27. Feng B, Pretorius PH, Farncombe TH, Dahlberg ST, Narayanan MV, Wernick MN, et al. Simultaneous assessment of cardiac perfusion and function using 5-dimensional imaging with Tc-99m teboroxime. J Nucl Cardiol 2006;13:354-61.
28. Porenta G, Cherry S, Czernin J, Brunken R, Kuhle W, Hashimoto T, et al. Noninvasive determination of myocardial blood flow, oxygen consumption and efficiency in normal humans by carbon-11 acetate positron emission tomography imaging. Eur J Nucl Med 1999;26:1465-74.
29. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
30. de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging 2005;32:98-101.
31. Kaneta T, Hakamatsuka T, Takanami K, Yamada T, Takase K, Sato A, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med 2006;20:203-8.
32. Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990;31:1749-56.
33. Hicks RJ, Herman WH, Kalff V, Molina E, Wolfe ER, Hutchins G, et al. Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. J Am Coll Cardiol 1991;18:101-11.
34. Pagano D, Lewis ME, Townend JN, Davies P, Camici PG, Bonser RS. Coronary revascularisation for postischaemic heart failure: how myocardial viability affects survival. Heart 1999;82:684-8.
35. Bax JJ, Fath-Ordoubadi F, Boersma E, Wijns W, Camici PG. Accuracy of PET in predicting functional recovery after revascularisation in patients with chronic ischaemic dysfunction: head-to-head comparison between blood flow, glucose utilisation and water-perfusable tissue fraction. Eur J Nucl Med Mol Imaging 2002;29:721-7.
36. Knuuti MJ, Nuutila P, Ruotsalainen U, Teras M, Saraste M, Harkonen R, et al. The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET. J Nucl Med 1993;34:2068-75.
37. 18F-FDG dynamic positron tomography and three-compartment analysis. Eur J Nucl Med Mol Imaging. 2005;32:806-12.
38. Baer FM, Voth E, Deutsch HJ, Schneider CA, Horst M, de Vivie ER, et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol 1996;28:60-9.
39. Bax JJ, Visser FC, Elhendy A, Poldermans D, Cornel JH, van Lingen A, et al. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. J Nucl Med 1999;40:1866-73.
40. Underwood SR, Bax JJ, vom Dahl J, Henein MY, Knuuti J, van Rossum AC, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004;25:815-36.
41. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997;30:1451-60.
42. Barrington SF, Chambers J, Hallett WA, O'Doherty MJ, Roxburgh JC, Nunan TO. Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging 2004;31:355-61.
43. Siebelink HM, Blanksma PK, Crijns HJ, Bax JJ, van Boven AJ, Kingma T, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 2001;37:81-8.
44. Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med Mol Imaging 2002;29:1257-66.
45. Bacharach SL, Bax JJ, Case J, Delbeke D, Kurdziel KA, Martin WH, et al. American Society of Nuclear Cardiology practice guidelines. J Nucl Cardiol 2003;10:543-56.
46. Schelbert HR, Beanlands R, Bengel F, Knuuti J, DiCarli M, Machac J, et al. PET myocardial perfusion and glucose metabolism imaging: part 2-guidelines for interpretation and reporting. J Nucl Cardiol 2003;10:557-71.
47. Schaefer WM, Lipke CS, Nowak B, Kaiser HJ, Buecker A, Krombach GA, et al. Validation of an evaluation routine for left ventricular volumes, ejection fraction and wall motion from gated cardiac FDG PET: a comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2003;30:545-53.
48. Saab G, Dekemp RA, Ukkonen H, Ruddy TD, Germano G, Beanlands RS. Gated fluorine 18 fluorodeoxyglucose positron emission tomography: determination of global and regional left ventricular function and myocardial tissue characterization. J Nucl Cardiol 2003;10:297-303.
49. Santana CA, Shaw LJ, Garcia EV, Soler-Peter M, Candell-Riera J, Grossman GB, et al. Incremental prognostic value of left ventricular function by myocardial ECG-gated FDG PET imaging in patients with ischemic cardiomyopathy. J Nucl Cardiol 2004;11:542-50.
50. Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Dierckx RA, de Boer J, et al. Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. J Nucl Cardiol 2006;13:210-9.
51. 99mTc-MIBI gated SPECT for evaluating myocardial viability and function. Ann Nucl Med 2004;18:375-83.
52. 18F- fluorodeoxyglucose using single photon emission computed tomography. Eur Heart J 1993;14:1675-82.
53. Drane WE, Abbott FD, Nicole MW, Mastin ST, Kuperus JH. Technology for FDG SPECT with a relatively inexpensive gamma camera. Work in progress. Radiology 1994;191:461-5.
54. Burt RW, Perkins OW, Oppenheim BE, Schauwecker DS, Stein L, Wellman HN, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995;36:176-9.
55. Bax JJ, Cornel JH, Visser FC, Fioretti PM, van Lingen A, Huitink JM, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol 1997;30:377-83.
56. Chen EQ, MacIntyre WJ, Go RT, Brunken RC, Saha GB, Wong CY, et al. Myocardial viability studies using fluorine-18-FDG SPECT: a comparison with fluorine-18-FDG PET. J Nucl Med 1997;38:582-6.
57. Mabuchi M, Kubo N, Morita K, Noriyasu K, Itoh Y, Katoh C, et al. Value and limitation of myocardial fluorodeoxyglucose single photon emission computed tomography using ultra-high energy collimators for assessing myocardial viability. Nucl Med Commun 2002;23:879-85.
58. 99mTc-tetrofosmin-FDG collimated SPECT. J Nucl Med 2000;41:1318-23.
59. 99mTc-sestamibi to assess myocardial viability and function in a single study. Eur J Nucl Med Mol Imaging 2005;32:195-202.
60. Gropler RJ, Geltman EM, Sampathkumaran K, Perez JE, Moerlein SM, Sobel BE, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 1992;20:569-77.
61. 11C acetate in patients with old myocardial infarction. Usefulness of low-dose dobutamine infusion. Circulation 1996;94:1834-41.
62. Yoshinaga K, Katoh C, Beanlands RS, Noriyasu K, Komuro K, Yamada S, et al. Reduced oxidative metabolic response in dysfunctional myocardium with preserved glucose metabolism but with impaired contractile reserve. J Nucl Med 2004;45:1885-91.
63. Miyabe H, Ohte N, Iida A, Narita H, Yoshida T, Kimura G. Evaluation of fatty acid beta-oxidation in patients with prior myocardial infarction in relation to myocardial blood flow, total oxidative metabolism, and left ventricular wall motion. Circ J 2005;69:1459-65.
64. 18F]FDG in patients with congestive heart failure. J Nucl Med 2001;42:55-62.
65. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001;103:2441-6.
66. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;40:271-7.
67. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.
68. Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2006;98:14J-18J.
69. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161-5.
70. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000;99:27-35.
71. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280-8.
72. Morrow DA, Givertz MM. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation 2005;112:3218-21.
73. Lopaschuk GD. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin Cardiothorac Vasc Anesth 2006;10:228-30.
74. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006;114:2130-7.
75. Torizuka T, Tamaki N, Kasagi K, Misaki T, Kawamoto M, Tadamura E, et al. Myocardial oxidative metabolism in hyperthyroid patients assessed by PET with carbon-11-acetate. J Nucl Med 1995;36:1981-6.
76. Hattori N, Tamaki N, Kudoh T, Masuda I, Magata Y, Kitano H, et al. Abnormality of myocardial oxidative metabolism in noninsulin-dependent diabetes mellitus. J Nucl Med 1998;39:1835-40.
77. Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993;22:1389-98.
78. Beanlands RS, Nahmias C, Gordon E, Coates G, deKemp R, Firnau G, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000;102:2070-5.
79. Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Non-invasive estimation of myocardial efficiency using positron emission tomography and carbon-11 acetate-comparison between the normal and failing human heart. Eur J Nucl Med 2000;27:319-26.
80. Nowak B, Sinha AM, Schaefer WM, Koch KC, Kaiser HJ, Hanrath P, et al. Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block. J Am Coll Cardiol 2003;41:1523-8.
81. Knuuti J, Sundell J, Naum A, Engblom E, Koistinen J, Ylitalo A, et al. Assessment of right ventricular oxidative metabolism by PET in patients with idiopathic dilated cardiomyopathy undergoing cardiac resynchronization therapy. Eur J Nucl Med Mol Imaging 2004;31:1592-8.
82. 11C-acetate PET after long-term cardiac resynchronization therapy. J Nucl Med 2006;47:378-83.
83. Lindner O, Vogt J, Kammeier A, Fricke E, Holzinger J, Lamp B, et al. Cardiac re-synchronization therapy: effects on myocardial perfusion at rest, after vasodilation and oxygen consumption. Nuklearmedizin 2006;45:10-14.
84. van Campen CM, Visser FC, van der Weerdt AP, Knaapen P, Comans EF, Lammertsma AA, et al. FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy. Eur J Nucl Med Mol Imaging 2007;34:309-15.
85. Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, Dibbets-Schneider P, et al. Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. J Nucl Med 2006;47:1565-70.
86. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000;279:E1104-13.
87. Li SH, McNeill JH. In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem 2001;217:121-9.
88. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006;47:598-604.
89. Knuuti J, Takala TO, Nagren K, Sipila H, Turpeinen AK, Uusitupa MI, et al. Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia 2001;44:184-7.
90. 18F]fluoro-6-thia-heptadecanoic acid. Diabetes 1999;48:1245-50.
91. 123I-heptadecanoic acid in subjects with impaired glucose tolerance. Diabetologia 1997;40:541-9.
92. Coort SL, Bonen A, van der Vusse GJ, Glatz JF, Luiken JJ. Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol Cell Biochem 2006 Sep 19; [Epub ahead of print].
93. McMillin JB, Taffet GE, Taegtmeyer H, Hudson EK, Tate CA. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc Res 1993;27:2222-8.
94. 18F]- fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-11.
95. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818-24.
96. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-31.
97. Mukai T, Nohara R, Ogawa M, Ishino S, Kambara N, Kataoka K, et al. A catheter-based radiation detector for endovascular detection of atheromatous plaques. Eur J Nucl Med Mol Imaging 2004;31:1299-303.
98. Hosokawa R, Kambara N, Ohba M, Mukai T, Ogawa M, Motomura H, et al. A catheter-based intravascular radiation detector of vulnerable plaques. J Nucl Med 2006;47:863-7.